Merck & Co., Inc. (MRK) Earnings Call Transcript & Summary

February 3, 2022

New York Stock Exchange US Health Care Pharmaceuticals earnings 60 min

Earnings Call Speaker Segments

Peter Dannenbaum

executive
#1

Thanks, Grace, and good morning. It's a pleasure to welcome everyone to Merck's conference call for the fourth quarter of 2021. Joining us on today's call are Rob Davis, our President and Chief Executive Officer; Caroline Litchfield, our Chief Financial Officer; and Dr. Dean Li, President of Merck Research Labs. Before we begin, there are a few things I want to flag. In our GAAP results, you'll notice certain items, including charges tied to acquisitions, costs from restructuring, and some other items as well. Keep in mind that these have been excluded from our non-GAAP results, and a reconciliation is available in our press release. I also want to remind everyone that some of what we say today could be deemed forward-looking statements under the safe harbor provision of the U.S. Private Securities Litigation Reform Act of 1995. These statements reflect Merck management's current beliefs and carry significant risks and uncertainties. Should our underlying assumptions turn out to be wrong, or should uncertainties come to pass, actual results could differ materially from what those forward-looking statements set forth. Our SEC filings, including Item 1A in the 2020 10-K, lay out certain risk factors and cautionary statements that could lead the company's actual results to differ materially from any projections in the forward-looking statements we make this morning. Merck has no obligation to publicly update any forward-looking statements. A slide presentation will accompany our speakers' prepared remarks during today's call. That presentation, along with today's earnings release and our SEC filings, can all be found in the Investor Relations section of Merck's website. With that, I'll hand the call over to Rob.

Rob Davis

executive
#2

Thanks, Peter. Good morning to all of you, and I appreciate you being on today's call. For Merck, 2021 brought substantial accomplishments and real advances, even though conditions proved difficult for everyone. We carried out our strategic priorities and made crucial moves that laid groundwork for achievement in 2022 and afterward. Our operational results came in strong, we sped up work across our extensive pipeline—molnupiravir among them—finished the Organon spin-off, and pursued significant strategic business development efforts. We head into 2022 carrying considerable momentum, and we're glad to show that through our preliminary revenue and EPS guidance. We keep transforming into a company that is more focused, more efficient, and growing at a quicker pace, with greater urgency to advance innovations that tackle serious unmet needs. That stays at the heart of our approach to help the patients we serve and, as a result, build long-term value for every stakeholder, our shareholders included. Strong revenue and earnings growth came through in our business. Quarterly total revenues rose 24%, and for the entire year they were up 17%. On the commercial side, our execution has been outstanding across each of our main performance drivers, among them KEYTRUDA, GARDASIL, and Animal Health; we made our first molnupiravir shipments to customers worldwide, and after the FDA emergency use authorization came through in late December, we moved considerably closer to fulfilling what we promised the U.S. government. Our committed teams worked hard, even over the holidays, to get 1.4 million courses of therapy delivered to the United States, United Kingdom, and other countries before the year ended. All through 2021, we put money into discovering, developing, producing, and commercializing medicines and vaccines, which supports our business's long-term sustainability, while also generating meaningful operating leverage and robust EPS growth. On the whole, 2021 saw us execute our strategic priorities strongly on every front: operational, commercial, clinical, and financial. Looking toward 2022 and out through 2025 and past that, we anticipate sustained strong growth. Our oncology portfolio stands to gain from uptake of many recent approvals and the anticipated launch of numerous added indications, earlier lines of therapy included. Global underlying demand for GARDASIL stays strong, and additional growth will come about from the investments we're making to expand manufacturing capacity; meanwhile our Animal Health business stays very well positioned to outgrow the market far into the future. Broadly speaking, we anticipate one more year of robust revenue growth in 2022. Although we'll keep investing in our pipeline, we're confident about attaining a leveraged P&L and considerable long-term operating margin expansion. Over the longer horizon, we are sharply focused on successfully steering through the headwind that likely biosimilar competition to KEYTRUDA will create at the end of the decade. Our aim is to grow through that period and past it. Even so, we'll at least aim to reduce that drag and cut down how long it takes before we're back to robust growth; there are several levers at our disposal for getting that done, fueling durable expansion far into the coming decade. To begin with, we plan to deepen our overall leadership position in oncology and use that standing to secure lasting success over the long haul. Establishing KEYTRUDA as a foundational therapy is something we've accomplished very well, and our aim is to get the most out of its potential and its effect on patients. Beyond that, we hold a growing lineup of oncology assets, both marketed and in development, that sit outside KEYTRUDA and present substantial growth prospects past 2028. Next, we have numerous significant franchises outside oncology that we believe can deliver lasting growth through the following decade — among them GARDASIL, which we think could potentially double by 2030, plus our pneumococcal portfolio and our Animal Health business, just to cite a few. Third, we anticipate producing exceptionally robust cash flow, which we plan to put toward value-enhancing business development so as to bolster our pipeline and add further engines of longer-term growth. And fourth, we'll push forward our in-house pipeline along with the opportunities we identify in vaccines, cardiometabolic, neuroscience and other disease areas. We're also devoting substantial resources to discovery research, which we see as the wellspring of innovation over the longer term. As part of our pledge to offer greater transparency around these efforts, we'll hold an investor event in the spring centered on our cardiovascular portfolio and pipeline. Along with speeding up our internal pipeline, as I mentioned, deploying our cash flow toward value-enhancing business development will be a central element of our strategy. We'll stay suitably aggressive when chasing compelling external innovation, and we'll bolster our pipeline using an approach that is science-led, yet portfolio informed. The Pandion and Acceleron acquisitions from last year illustrate our approach nicely. We're taking calculated risks, and we'll keep concentrating on creating value in areas of unmet need; we possess the operational capabilities, financial capacity, scientific prowess and enough runway before the decade ends for business development to matter greatly in our pursuit of long-term sustainable growth. Although our business development record is strong, we recognize that more must be done. Lastly, we've gone further in embedding key environmental, social and governance objectives at the heart of our business. In December, we finished the first issuance of a $1 billion sustainability bond. We plan to direct the net proceeds toward backing projects and partnerships within the company's priority ESG areas and toward helping advance United Nations Sustainability Development Goals. We've also taken action to speed up global access for molnupiravir via our groundbreaking access strategy, among them a recent agreement with UNICEF covering up to 3 million courses of therapy to add to the supply available for distribution in low- and middle-income countries. Moreover, this morning, we announced plans to host our first ESG investor event on February 23. We think that robust results on the key ESG measures line up closely with what Merck stands for and what we're trying to accomplish, and we're eager to share more about how dedicated we are in this area. Before handing things to Caroline, though, I'd like to pause and acknowledge Frank Clyburn. After 14 years of meaningful contributions, Frank is departing Merck to take on the CEO role at IFF. I want to express my gratitude to Frank for the strategic vision and operational excellence he brought in helping make Merck a worldwide leader in oncology, and for the strong way he led our Human Health business. We send Frank and his family our very best wishes as he starts this new endeavor. Frank will certainly be missed, yet with the deep and talented team we have in place, we're well positioned to keep up our strong momentum, and we expect to name new leaders shortly; with that, I'll hand it to Caroline, who will walk through how our business performed along with our financial results and outlook. Caroline?

Caroline Litchfield

executive
#3

Thanks, Rob, and good morning, everyone. For our business, 2021 brought outstanding results. We achieved strong growth on the top line of 17%, along with 33% growth on the bottom line. Even with the difficulties created by the continuing pandemic, our teams moved quickly and carried out their work exceptionally well. In addition, we take great pride in the substantial work done to deliver monotherapy to patients around the world. These outcomes strengthen the trust we place in our science-driven approach and in our expectations for robust growth. We will keep putting money into our portfolio and pipeline, and into business development too, so that growth is maximized in both the near term and the long term, and so that value is created for patients and for shareholders. Let me now move to what happened in the fourth quarter. Revenues for the whole company came to $13.5 billion, which is 24% higher, or 23% higher when you leave out the effects of foreign exchange. Molnupiravir brought in $952 million in revenue, which amounts to 9 percentage points of growth. From here on, everything I say will be on an ex-exchange basis. Human Health continued its strong trajectory, growing 23%, driven by our core pillars along with the boost from molnupiravir. Animal Health also delivered a solid quarter, posting an 8% sales increase, led by companion animal offerings. Turning to how our major brands performed in Q4: in oncology, KEYTRUDA climbed 16% to reach $4.6 billion, reflecting sustained strong demand globally; here in the U.S., KEYTRUDA continues to demonstrate lasting momentum across every major tumor type and is benefiting from recent launches in neoadjuvant and adjuvant triple-negative breast cancer, renal cell carcinoma and cervical cancer. In immuno-oncology, KEYTRUDA continues to strengthen its leading position and remains firmly established in non-small cell lung cancer, where it draws 8 of every 10 qualified new patients even with rivals in the mix. Outside the United States, growth for KEYTRUDA continues to be driven by lung cancer together with the ongoing launches in head and neck and RCC; our reach into earlier lines keeps broadening; we were delighted to secure 2 further adjuvant approvals during this quarter, one in RCC and one in melanoma; thanks to these approvals, KEYTRUDA has now been granted 5 indications across earlier-stage cancers. Should approval come through, we also anticipate moving into adjuvant lung cancer, encouraged by the positive top line results from the KEYNOTE-091 trial. With solid clinical evidence behind it, we believe physicians' trust in and knowledge of KEYTRUDA will serve us well as we expand into earlier stages of disease. Lynparza continues to hold the top position among PARP inhibitors. A 33% increase came from our breast cancer approval as well as ongoing adoption of newer indications such as prostate. Launching in a wider prostate patient group, should the PROpel trial support it, is a major opportunity in our view. Lenvima's revenue rose 31%, powered by RCC and endometrial cancer within the United States; early signals on new patient share have been highly encouraging since KEYNOTE-581 launched in first-line RCC. We likewise feel great enthusiasm about the recent introduction of WELIREG for individuals with specific VHL-associated tumors. WELIREG keeps drawing a lot of attention from scientific leaders, providers, and patients, and it's off to a promising start; going forward, we expect to broaden its reach into wider RCC indications. Once again our Vaccines portfolio posted strong growth, powered by GARDASIL, which rose 50% to $1.5 billion and close to 40% for the full year. Beyond the U.S., solid growth came from strong underlying demand across every key geography, especially China, along with greater supply. That growth more than made up for the U.S. The decrease came from how CDC orders were timed and from restocking that agency's reserves in Q4 2020; COVID shots being given first to younger groups likewise had an impact on HPV vaccination rates. Demand for GARDASIL remains robust worldwide, as more and more people regard it as a means of guarding against particular cancers tied to HPV in women as well as men. In our acute care hospital lineup, BRIDION posted a 24% gain in sales, driven by heavier reliance on agents that reverse neuromuscular blockade and by this product's growing portion of that category. Animal Health delivered yet another quarter of impressive expansion, posting an 8% sales increase. Sales for companion animals rose 26%, fueled by worldwide need for parasiticides—among them the BRAVECTO product line—along with vaccines. Remember that distributor buying patterns shifted, and that weighed on the prior year's figures. Livestock revenue stayed level, because robust international appetite for poultry and swine offerings was counterbalanced by a difficult comparison versus a year earlier, when an additional month of Antelliq sales landed in the fourth quarter of 2020. I'll walk you through the remaining portions of our P&L now, and everything I say will be on a non-GAAP basis. Gross margin reached 74.8%, a decline of 0.2 percentage points. Just to remind everyone, we share molnupiravir profits on a 50-50 basis with Ridgeback, our partner, and that appears in cost of sales, bringing our gross margin down. The effect was mostly offset by favorable mix along with fewer discards. Operating expenses climbed 3%, reaching $5.3 billion, reflecting our continued investment in growth drivers and the pipeline. Other expense came to roughly $50 million. For the full year, our tax rate was 11.2%, which is below what we had guided previously, because the mix of income and expense turned out better than our earlier estimate. In the fourth quarter, the effective tax rate was 4.3%, which reflects both the lower full year rate and a foreign tax credit. Taking everything together, we earned $1.80 per share. Before we move on, I want to point out that the operating results we delivered on an underlying basis came in near the top of what we had anticipated, and between the sales generated by molnupiravir and the benefit we saw from taxes, earnings per share exceeded the guidance we had given earlier. Let's now shift to our non-GAAP outlook for 2022. We feel assured that the strong underlying momentum across our business will continue, and on top of that we expect added benefit from increased molnupiravir revenue. We're projecting revenue in a range of $56.1 billion to $57.6 billion, representing growth of 15% to 18%, and embedded in that number is an approximate 2% headwind from foreign exchange based on rates from the middle of January. On gross margin, we anticipate roughly 74%. When it comes to operating expenses, anticipate an increase in the mid- to high single-digit range, partly because we're adding R&D costs tied to the Acceleron acquisition. Under other income and expense, we're anticipating around $350 million in expense. For the entire year, we're assuming a tax rate of 13% to 14%. We're also assuming 2.53 billion shares outstanding. Putting all that together, we anticipate EPS between $7.12 and $7.27, which represents 18% to 21% growth. That range factors in a negative currency effect of roughly 1%, again using mid-January rates. As you build out your models, here are a few things to keep in mind. To start with molnupiravir, we're thrilled about the regulatory authorizations we've secured so far and think this drug is going to be a crucial therapeutic choice in the fight against the continuing pandemic. We've made public a series of supply and purchase deals that cover about 10 million courses of treatment. Given the agreements that are currently in place, we feel confident about reaching $5 billion to $6 billion in revenue during 2022, with more weight on the first half of the year. Moving on, we're expecting KEYTRUDA to keep delivering robust growth, and it ought to get a lift from greater expansion in markets outside the U.S. as well as the ongoing ramp of launches that happened recently around the world.

Caroline Litchfield

executive
#4

When it comes to GARDASIL, our expectation is still for solid demand, and with more supply coming, that should produce significant growth compared with a year earlier, though it won't match the rate seen in 2021. Within the U.S., growth should come from greater uptake among the mid adult cohort and from people catching up on doses they missed because of the pandemic. Beyond the U.S., we still anticipate robust demand across regions, especially China, and from the relaunch in Japan. HPV vaccination rates worldwide are still low, and our view remains that GARDASIL has a substantial growth opportunity. Turning to pneumococcal, we're enthusiastic about the recent adult launch of VAXNEUVANCE and about the possible chance of a pediatric approval, since pediatric accounts for a bigger share of that market. That said, we anticipate a partial offset from the effect on U.S. sales of PNEUMOVAX 23, since the market keeps moving toward newer pneumococcal conjugate vaccines. We also anticipate modest LOE pressure on JANUVIA during the second half of 2022, when we lose exclusivity in some of the bigger ex-U.S. markets. In Animal Health, our broad and innovative portfolio leaves us well positioned to deliver above-market growth once more in 2022 and beyond. Lastly, looking ahead to 2025, we stay confident that we can achieve strong revenue growth, driven mainly by our derisked portfolio, along with an operating margin above 43%. Our priorities for capital allocation haven't changed. First, we'll keep prioritizing investments in our business and pipeline to fuel near- and long-term growth. We'll also keep augmenting our internal pipeline via strategic business development. We were active during 2021, with the acquisitions of Acceleron and Pandion among them, and we plan to pursue further value-enhancing opportunities. We're still committed to the dividend, with the aim of raising it over time. Where we have excess cash, we'll return it to shareholders via share repurchases. In closing, our fourth-quarter growth highlights how confident we are in the fundamental strength of our business and in worldwide demand for our innovative medicines and vaccines. We continue to be in a position of financial and operational strength, and by continuing to execute we'll deliver on that promise now and well into the future; with that, I'd like to hand the call over to Dean.

Dean Li

executive
#5

Thank you, Caroline. Good morning, everyone. I'll give a quick recap of key accomplishments from 2021, and after that I'll walk through what's happened since our previous earnings call. During 2021, we achieved significant progress throughout our wider pipeline, securing approvals for new molecular entities such as VAXNEUVANCE, VERQUVO and WELIREG, along with an EUA for molnupiravir. We likewise advanced in women's cancers, obtaining U.S. regulatory approvals for KEYTRUDA in cervical, endometrial and triple-negative breast cancer. All told, we gained over 30 approvals and submitted more than 20 NDAs and SBLAs across the United States, EU, Japan and China. Looking to 2022, our aim is to extend this progress and momentum. Now I'll discuss key regulatory milestones and clinical updates covering our molnupiravir, oncology, pneumococcal, HIV and cardiovascular programs. With the pandemic now in its third year, the Omicron variant keeps wreaking havoc on our communities and health care systems. Within the United States by itself, roughly 2,000 deaths are occurring each day. Vaccines and treatment options could potentially help us fight this pandemic. Since molnupiravir received its first authorization from the U.K. in November, authorizations have come through in 9 additional countries, among them an emergency use authorization in the United States and a special approval for emergency in Japan. Beyond that, other nations have granted authorizations to our voluntary license holders. Data from the MOVe-OUT study, which appeared in the New England Journal of Medicine at the end of last year, showed that molnupiravir cut hospitalizations and fatalities considerably in adult patients who faced the highest likelihood of advancing to severe illness. For doctors and their patients, what matters most is this: among those receiving molnupiravir, deaths dropped by approximately 90%. These results verify that for certain adults confronting elevated risk of serious disease, molnupiravir represents a beneficial oral therapeutic option. According to the Director of the United States CDC, therapeutic interventions ought to be prioritized for individuals at greatest risk of progression, among them those with specific comorbidities. Molnupiravir, in our view, has a limited tendency to interact with other medications. That makes it a significant and valuable choice for appropriate COVID-19 patients receiving treatment for pre-existing conditions like heart disease, hypertension and diabetes, and also for individuals whose liver or kidney function is impaired, consistent with local guidance. To date, this pandemic has moved forward in a series of waves driven by SARS-CoV-2 variants, with Omicron being the most recent. Data from several independent studies, which we presented last week, demonstrated that molnupiravir shows activity against the Omicron variant in vitro. Each new wave carries its own public health and disease traits, together with matching hurdles for treatment and prevention. The danger that fast-appearing variants represent highlights why we need therapies that are hard for the virus to evade and that go after parts of its biology that stay conserved over time. Because we understood how vital an oral antiviral is, we made the decision to produce molnupiravir and to have doses on hand for U.S. patients the moment emergency use authorization came through. Caroline mentioned this, and indeed we delivered on that commitment, getting this crucial therapy out to people. Working alongside governments and partners across the globe lets us stay in front of developments and grow Merck's part in fighting this pandemic. Turning now to oncology, we continue to build on our position. We've hit several recent milestones that really highlight our strategy of targeting cancers at earlier stages, where we might achieve better outcomes by reducing the likelihood that the disease comes back. With KEYTRUDA in the adjuvant setting for renal cell carcinoma, we secured approval from the FDA and the European Commission, plus FDA approval for certain stages of melanoma. On the RCC side, that approval was based on KEYNOTE-564. For certain patients facing intermediate high or high risk of recurrence in the adjuvant setting, KEYTRUDA stands as the first and only immunotherapy option. And in melanoma, the approval relied on KEYNOTE-716 and covers adjuvant treatment for patients 12 years and older with Stage IIb and IIc disease after complete resection. With these two authorizations, individuals now have valuable new choices proven to reduce the chance of the disease coming back. Along those same lines, we shared encouraging findings not long ago from the KEYNOTE-091 trial, also called PEARLS, which examined KEYTRUDA given as adjuvant therapy to people who had surgery for Stage Ib to IIIa non-small cell lung cancer. During an interim look at the data, the study met one of its two main goals, demonstrating a statistically significant gain in disease-free survival across every subgroup among those who received KEYTRUDA rather than placebo. The study will continue to evaluate DFS among patients with tumors that have elevated PD-L1 expression — that being the second dual primary endpoint, which at the planned interim analysis had not reached statistical significance — along with overall survival, a key secondary endpoint. Data coming out of the Phase III OlympiA trial means we keep gaining ground in women's cancer. Regarding Lynparza, the FDA has given priority review to the adjuvant treatment of patients who have BRCA-mutated HER2-negative, high-risk early breast cancer and were previously given chemotherapy, whether before or after surgery. An FDA decision is anticipated in the first quarter of 2022. Now shifting to the wider portfolio. Regarding the gefapixant new drug applications, the FDA sent a complete response letter asking for more information about how efficacy is measured. On the safety side, nothing concerning came up with gefapixant, and we'll continue collaborating with the FDA on next steps as we work to address the considerable unmet need among chronic cough patients. Turning to Japan, we're happy to share that Lyfnua—the trademark name for gefapixant—has been approved by the Ministry of Health, Labor and Welfare for adults dealing with refractory or unexplained chronic cough. Our pneumococcal disease program keeps building momentum after the U.S. approval back in July 2021. Then in December, the European Commission granted approval for VAXNEUVANCE among people 18 and older. We also shared in December that the FDA has given priority review status to our supplemental application for VAXNEUVANCE for use in kids. A key point: VAXNEUVANCE includes serotypes 22F and 33F and delivers a strong response against other major disease-causing serotypes, such as serotype 3, so it could potentially stop more invasive disease in children. A regulatory decision is anticipated in the spring of this year. Merck has a long, rich history in HIV research, and our commitment to those living with the virus remains firm. Once the FDA placed a clinical hold on ongoing trials of islatravir, we have been working to understand both the data and the rationale for that action. We have faith in what the nucleoside reverse transcriptase and translocation inhibitor approach can offer for preventing as well as treating HIV, and we plan to provide updates down the road. Turning to the rest of our pipeline. In Q4, as Rob mentioned, we closed our purchase of Acceleron. Sotatercept, its top candidate, fits our pipeline extremely well and could deliver a new way of addressing pulmonary arterial hypertension. Integration is moving forward as expected, and the Phase III effort remains on schedule. We intend to share more about our cardiovascular pipeline at an investor event this spring; to wrap up, 2021 proved to be an outstanding year in which we showed we could move forward both internally and externally developed programs. We enter 2022 in a strong position to keep up our momentum with two goals: leading in oncology by 2025 and holding that spot past 2028, all while broadening our reach into additional therapeutic areas. I'm eager to share more updates over the next year. At this point I'll hand the call back to Peter.

Peter Dannenbaum

executive
#6

Thank you, Dean. Grace, would you please start the Q&A? <<operator_script>> Thank you.

Geoff Meacham

analyst
#7

I suppose this is one for Dean or Rob. When it comes to molnupiravir, how significant is it from a strategic standpoint? If resistance doesn't show up, is the aim to bring in as much revenue as possible during this year? Or are you investing in a possible combination so that this business might become a longer-lasting contributor?

Rob Davis

executive
#8

Right. Geoff, I appreciate the question. When we think about molnupiravir, you clearly heard Caroline discuss the guidance we're providing for this year, but I believe you've identified something important, since we truly do see promise for molnupiravir past the present circumstances involving COVID-19 and the pandemic, because it has such strong activity across RNA viruses more generally, and in our view, it may be effective against all coronaviruses. We also demonstrated this lately through 6 preclinical studies, showing solid performance against the Omicron variant, and we expect it will keep working against variants that arise later. That said, perhaps I should hand things to Dean so he can say more about how we're approaching this from a development standpoint over the longer term.

Dean Li

executive
#9

Okay, if I could, let’s take a moment to put into perspective the number of deaths occurring each day here in the United States. Honestly, where we stand right now is pretty shocking. And I’d like to stress that molnupiravir, as everyone knows, is taken by mouth; it works to lower hospitalizations and fatalities. I genuinely believe that when we consider the mortality rate in the U.S. and globally, having treatments available that can cut death rates by more than 80%, 85%, 90% is going to matter a great deal; molnupiravir is among the medicines capable of achieving that, and I think that point deserves to be highlighted. Now, turning specifically to molnupiravir, the patients we must worry about regarding drug-drug interactions, renal insufficiency, or liver insufficiency are frequently the very ones facing the greatest danger. And the reality that molnupiravir possesses a profile that proves genuinely beneficial for those individuals matters. I want to stress that from first principles, the entire mechanism and the molecule itself were engineered to be as resistant to variants as theoretically achievable; and what we observed with Omicron, and potentially what lies ahead with additional variants, shows that the theoretical turns into reality. Take Omicron, for instance—suddenly, a whole set of antibody therapies stop working. Then another thing I’d point out is that when we submitted our EUA in October, we also made a commitment that we would be capable of manufacturing, supplying, and distributing this medication right away. And I believe it’s been proven that when we filed our EUA in October, we were in that position; and we showed, upon receiving an EUA in late December, just how quickly we could get it out. And I simply want to stress that, in my view, when someone compares the death rate at the time we submitted our EUA to the death rate today, it is three times greater. So I just want to call attention to that. Looking ahead, I suppose there are various possible extremes one might consider. And those extremes would be, alright, perhaps a highly lethal sub-variant could emerge. In that case, the matter of us having a resistance profile we feel very confident in could prove extremely significant. Another extreme scenario is that this shifts toward becoming more endemic. So everybody is catching it; it isn’t necessarily fatal for healthy individuals. Yet in that scenario, as with flu, it’s the most vulnerable patients who require treatment, and that most vulnerable group often consists of those individuals you must worry about concerning drug-drug interactions, renal and liver insufficiency. So within that framework, specifically for COVID-19, that’s how we approach molnupiravir. Regarding your question about whether the field eventually must seriously consider combination, I believe it does. And I truly believe it matters that we possess a range of several different ways of acting, since with every viral illness I'm aware of, the virus tends to be quite skilled at dodging various mechanisms. And I think we might need to consider this combination question that you brought up. And we've put in both our own internal resources and other mechanisms of action. And we're currently talking with others who have a different mechanism of action; so the key point is, I believe, we must hold the view that we have to be ready, that we will require multiple choices, and molnupiravir plays a significant role in the arsenal that the United States and the world will need to have.

Caroline Litchfield

executive
#10

If I can jump in here, this is Caroline speaking. Our guidance for revenue this year sits at $5 billion to $6 billion. That figure assumes roughly 10 million courses. Picking up on what Dean said, our priority as a company is making certain supply is sufficient, whatever direction events take. As such, we remain committed to the 10 million courses that we manufactured in 2021, and to more than twice that amount in 2022. That means we will have over 30 million courses available, in order to support how the pandemic develops and how molnupiravir gets used.

Chris Shibutani

analyst
#11

Regarding KEYTRUDA, a key element of that plan for staying ahead is the adjuvant chance, in both combo forms. When it comes to the adjuvant setting, could you say a bit more about what you believe you're observing up to now and how things are moving along? And as for the combos, it appears the data is set to be reported later, around the '24 and '25 period. Dean, maybe there's a possibility we could get an earlier peek than that on any of those combo attempts?

Dean Li

executive
#12

Correct. I simply want to stress this. We have 2 kinds of combos. There are IO-IO pairings, and I believe that's what you mean when it comes to KEYTRUDA, whether it's with our TIGIT, LAG-3, CTLA4 and so on; and you're correct, those readouts depend on events, and the fact sheet, and that's going to be — we'll find out where it stands, but I'd say your timeline is a sensible kind of timeline for Phase III readouts. When it comes to other combos, I'd like to point you toward KEYTRUDA paired with chemotherapy, with other ADCs we've collaborated on with other firms; but I'd also direct your focus to the readouts of KEYTRUDA plus Lenvima that keep accumulating, and KEYTRUDA plus Lynparza. And the reason I consider that significant is we think about how to boost the immuno-oncology profile of KEYTRUDA using other IO agents. But also, as we observe Lynparza and LENVIMA, they are — they provide us readouts on how to approach DNA repair and with combination in second and third generation of various kinds of compounds in that area; and also regarding Lenvima, where you're examining blocking vascular endothelial growth factor, RTKs, it offers us an idea about how to consider drugs like WELIREG, which likewise operates in that same kind of space. And so we're quite eager to see how WELIREG performs in sporadic renal cell carcinoma. And after that we'll ask ourselves, beyond renal cell carcinoma, where else ought it be used where an anti-angiogenesis agent has proven to be effective.

Rob Davis

executive
#13

Absolutely, Chris — and let me address that initial part of what you asked regarding how we view the adjuvant setting. Clearly, there's a great deal of enthusiasm on our side about advancing into earlier stages of treatment. We see this as a genuine growth opportunity. Of course, the momentum behind KEYTRUDA stems from our capacity to enter new indications and keep widening our reach. Consider that during 2021 by itself, we received 21 approvals covering new or broader uses for KEYTRUDA. Among those, 3 fell within the adjuvant setting — adjuvant triple-negative breast cancer, adjuvant renal cell carcinoma, and a shift into a Stage II cancer with adjuvant melanoma. So that represents meaningful growth. When you take that together with the additional indications already in hand plus the other adjuvant melanoma uses and what we anticipate having shortly through KEYNOTE-091 in adjuvant non-small cell lung cancer, what we see is a push toward earlier stages, which should account for roughly 50% of the growth for this drug, KEYTRUDA, through 2025. And our expectation is that by 2025, around 30% of our overall revenue will derive from the adjuvant indications we hold; so here is a space where we're beginning to deliver results. I believe we will demonstrate that the full breadth of what KEYTRUDA can accomplish — in maintenance as well as in the metastatic setting — will prove highly significant as we establish leadership over the long term.

Peter Dannenbaum

executive
#14

And to be clear, Rob is referencing the U.S. markets.

Steve Scala

analyst
#15

I want to ask about a pipeline agent that gets less attention. According to Sanofi, you can't really see any clear proof that the Merck RSV monoclonal antibody works better than Sanofi's monoclonal antibody, and Sanofi's lead is so large that its dominance is beyond doubt. So what does Merck think? And if Sanofi has it wrong, what makes your antibody the superior one?

Dean Li

executive
#16

Right. I need to tread somewhat carefully here, since these questions concern a drug belonging to a different company. My view is that it matters a great deal to have monoclonal antibodies capable of treating RSV in a patient population that truly needs them. Data from us is on the way, and what it shows remains to be seen; even so, our belief is that there's a chance to deliver a highly effective drug that's genuinely simpler to give to that patient population. So direct comment makes me somewhat reluctant, but our confidence in the profile of our RSV antibody studies is strong; and we'll simply have to wait and find out what the clinical data shows once that clinical data arrives.

Jon Miller

analyst
#17

Jon Miller here, filling in for Umer. Regarding islatravir, clearly the extended duration and prolonged PK profile represent the key selling point; however, could there be any opportunity to bypass CD4 monitoring, or perhaps sidestep certain potential product concerns that you have been examining or assessing? If you remain with a sub milligram daily dose instead of attempting to advance toward weekly or monthly dosing, might that be a viable route ahead for islatravir within the HIV franchise?

Dean Li

executive
#18

Yes. Allow me to address that. We are currently assessing a substantial collection of data. You brought up lymphocyte trends that have been seen across various trials we have conducted. I would highlight that our Phase III study involving islatravir and doravirine showed the efficacy and simply the highly efficacious character of islatravir within that regimen, which is Q day; we will have near-term assessments of upcoming options, yet we remain very dedicated to this longer acting perspective as well. So addressing your question, we possess data concerning Q day islatravir, doravirine, and it is highly efficacious. We intend to examine the collection of data concerning alternative approaches to keep enabling that extended sort of resident time, to allow for a less frequent either PrEP or treatment. And we are assessing those data right now.

Mara Goldstein

analyst
#19

Over the past 2 weeks or so, several of your rivals have weighed in with remarks about M&A valuations. Given that you've talked about acquisitions as one piece of your strategy, I'd like to hear your take on where valuations stand in relation to the broader plan of keep supplementing the company's pipeline.

Rob Davis

executive
#20

Yes. Appreciate that question, Mara. As you noted, what we're observing in the biotech sector is that valuations have come down substantially recently. In my view, it's premature to determine whether this represents a lasting rebasing across the market or merely a short-lived shift in the marketplace. We'll need to watch how that unfolds. Beyond that, something else that may matter is the trajectory of investment flows entering the sector. You're already seeing IPOs beginning to decelerate. It will be worth watching whether cash investments likewise begin to decelerate as investors seek to put money into the sector against a backdrop of lower valuations, as you mention. Whether that pushes sellers toward accepting a restatement of value that lets us complete deals at varying levels, only time will tell; however, it doesn't alter how important we believe business development is for the company. Clearly, our foremost and primary focus is on advancing and speeding up our own pipeline, yet we recognize the need to bolster it. We will keep concentrating our efforts in this area. And I'm confident we'll locate the opportunities in which the scientific opportunity aligns with our capabilities and in which we identify solid value that lets us execute value-enhancing deals, no matter what the market conditions are.

Tim Anderson

analyst
#21

This is Adam, calling in for Tim Anderson. Regarding the oral PCSK9 program you mentioned, you've said Phase II begins in 2022. If we assume completion takes 2 years, how would a Phase III study be designed regarding its duration and the comparator used? My guess is that results might arrive before the late 2020s.

Dean Li

executive
#22

Yes. I appreciate that question; it concerns our oral PCSK9 medication. We shared the Phase I readouts concerning it. The Phase II readouts are going to matter a great deal. As everybody knows, cardiovascular risk represents an enormous danger across the board. In fact — one could see it as an epidemic that keeps going, and there will be two key factors to consider. First, as we move the oral PCSK9 forward, the LDL-lowering biomarker is a strong one, established as significant, and it has created a registration pathway built on that, even before having readouts related to cardiovascular outcomes, regarding death and heart patient endpoint; so we think we'll need to do both, yet we're quite keen to learn how effectively this agent performs in our Phase II trials at pushing LDL levels down, and that will give us confidence to truly move this ahead for patients. Still, lowering LDL will be a key registrational element that has served as a path for other medications too. Yet we will additionally need to conduct an outcome study on top of that.

Analyst

analyst
#23

This is Charlie Young calling in on behalf of Matthew. Regarding how you expect VAXNEUVANCE to perform at launch during this year, and maybe the following one too, particularly now that the pediatric indication has been approved — could you speak to that?

Rob Davis

executive
#24

Yeah, so it probably goes without saying that we have a lot of enthusiasm for VAXNEUVANCE and for the chance to present it, beginning with the adult indication, as you mentioned, which we've already gotten. And as I think you're aware, the NMWR did come through and confirm the ACIP recommendation. That puts us in a position where reimbursement has been set up in the market, and shipping of the product has started. When we examine this, a genuine opportunity stands out, since if you consider how VAXNEUVANCE looks alongside PNEUMOVAX 23, what you have is an option offering the widest coverage. Across the two, VAXNEUVANCE contains 15 serotypes. Another 9 serotypes get added, 4 of them found only in PNEUMOVAX 23. And when we consider that coverage, clearly, for something like serotype 3, we demonstrated through VAXNEUVANCE that we're highly competitive, and possibly even better than what else is on the market. We also recognize that serotype 3 plays a major role in causing and driving disease, just like serotypes 22F and 33F, both of which ours includes too. So from our perspective, there's very wide coverage, plus meaningful coverage against serotypes that cause a great deal of disease. On top of that, we hold key data demonstrating the drug's performance in at-risk and immunocompromised patients, which is going to appear in the label — it's already there; so our position is strong. Naturally, we'll need to compete hard on the commercial side, though we believe our position sets us up well for that. And our attention is already turning toward what lies ahead in pediatrics. At the moment, with any luck, we'll see — given the PDUFA date in April, we're hoping to see the chance to bring that drug to market. Still, it's clear we'll take the momentum built from the adult launch and use it to move into the pediatric setting; so far everything has gotten off to a solid start, contracting is progressing nicely, and we've begun well. Thank you.

Andrew Baum

analyst
#25

I want to ask about islatravir. Can you rule out that mitochondrial toxicity is what's driving the lymphocyte reduction? Alternatively, if you lack a clear path toward longer dosing period formulations, would you still submit for approval of the once-a-day combination?

Dean Li

executive
#26

We lost a bit of your audio. Regarding the mechanism behind the lymphocyte trends we've disclosed moving downward — we are examining the mechanism of action. Let me make just two quick points. First, there's the question of whether there might be approaches to circumvent this by examining the dose that was given. And the second question concerns the mechanism itself. That mechanism is still under evaluation. I think what you asked relates to mitochondrial toxicity. Based on the data we currently have, that isn't the first area we would look at; however, I don't want to exclude anything at this moment, since we're reviewing all the data right now.

Louise Chen

analyst
#27

I'd like to ask whether the reports regarding supply chain challenges for oral antivirals are correct. And assuming they are, what steps are you taking to address them?

Rob Davis

executive
#28

Yeah, thanks for bringing that up, Louise. When you examine where things stand — and my guess is your attention is mostly on the U.S. — we managed to get courses of therapy into the United States prior to the close of the year; slightly more than 900,000 courses of therapy reached them. From that point onward, we keep adding to that total. And once this week wraps up, we ought to have the complete 3.1 million courses sent to the distribution hubs that they operate. Clearly, from there it becomes a matter of us coordinating with the government, though the decision on placement and method of getting it from those hubs out to pharmacies and local markets rests with the government. What we're truly concentrating on in our conversations with the government, I believe, is finding ways to expand the messaging so people grasp how to discover, and where to visit, to obtain antivirals. The government maintains locator sites online. And we're doing everything possible to ensure people realize they should check there, since the drug is available in the marketplace — you simply need to determine where to locate it. And we'll keep collaborating with the government in whatever manner they require to guarantee access happens as swiftly and widely as we can manage. Naturally, our attention extends past the U.S. too, and I'm quite confident about our efforts. You've likely seen our announcement of an agreement with UNICEF covering 3 million courses. That effort is really about helping us speed up access for low- and middle-income countries while we await the generic manufacturers. So we held the licenses as they increase production. So with luck, that fills the gap in those markets while we wait for generics to eventually become available.

Daina Graybosch

analyst
#29

I want to return to KEYTRUDA in oncology and the IO combo. So this year, I believe we'll see several randomized TIGIT readouts from Roche. And as someone said before, you have numerous TIGIT and LAG-3 trials on the way. Could you discuss how your development approach might be differentiated for these IO-IO combinations? Specifically, can you point to any place where your foundational position with KEYTRUDA might provide an edge?

Dean Li

executive
#30

Let me address the scientific aspect of that. Thanks for asking. I'd stress the broad principle we hold, which is that we think there are ways to boost the immuno-oncology access of PD-1 by adding a different checkpoint inhibitor. We think that will potentially be a distinct checkpoint inhibitor or a distinct addition to PD-1 depending on a different tumor cut. So we aren't convinced there's a single additional checkpoint inhibitor you could add to PD-1 that would deliver as wide an impact as P1 does on its own. So our approach has been to put money into CTLA-4, to put money into TIGIT, to put money into LAG-3, to put money into ILT4. I think the approach of some of our peers is to make a bigger wager on each of those combos more broadly; so I think that's something I consider really important. The second thing I'd stress is you need to demonstrate contribution of components, and you need to demonstrate that whatever you add onto the PD-1 is genuinely superior to the PD-1. And the reason I want to stress that is that one should also examine what the base of our PD-1 response looks like relative to others; so it is my belief that targeting the PD-1 axis is, in general, more effective than, for instance, a PD-L1. So that gives us a differentiating position too. And then the third matter is, particularly in lung, where physicians are very at ease regarding where we stand with PD-1, with our PD-L1 monotherapy differentiation as well as PD-1 plus chemo; and also we're pushing our PD-1 into earlier stages of cancer, for instance, in lung and others. I think that gives us a leg-up too. So three things. One is how we think strategically about IO-IO combinations; and then the second thing is regarding PD-1 versus a non-PD-1 position, so PD-1 versus a PD-L1; and also our ability to paint the whole picture from adjuvant all the way to later stage is something that I think gives physicians enormous comfort in our base drug.

Peter Dannenbaum

executive
#31

Alright, thanks Dean. Thanks, Daina. And I appreciate everyone’s thoughtful questions today. We know a peer call is beginning at this moment, so we’ll keep that in mind. Should anything else come up, feel free to contact the IR team whenever you like. We do value the solid questions today and your interest. Thank you.

Rob Davis

executive
#32

Thank you.

Operator

operator
#33

Everyone, that brings us to the end of today's call. We appreciate each of you for being here. At this point, you're free to hang up.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Merck & Co., Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Merck & Co., Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Merck & Co., Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.